Skip to main content
新赣江 logo

新赣江 — Investor Relations & Filings

Ticker · 920367 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 389 across all filing types
Latest filing 2023-08-28 Interim / Quarterly Rep…
Country CN China
Listing Beijing Stock Exchange 920367

About 新赣江

http://www.xgjyy.com/

Jiangxi Xinganjiang Pharmaceutical Co., Ltd. specializes in the research, development, production, and distribution of a diverse range of pharmaceutical products. The company's portfolio encompasses chemical active pharmaceutical ingredients (APIs), chemical drug preparations, and traditional Chinese medicine (TCM) formulations. Its core product offerings target therapeutic areas such as cardiovascular and cerebrovascular health, digestive system disorders, and nutritional supplementation. Key products include Ginkgo Biloba extract, Vitamin C, and various gastrointestinal medications. By maintaining an integrated value chain that spans from raw material synthesis to finished dosage forms, the company ensures quality control and supply chain efficiency. It focuses on delivering high-quality healthcare solutions through continuous innovation in pharmaceutical manufacturing and formulation technology.

Recent filings

Filing Released Lang Actions
2023年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a '2023 半年度报告摘要' which translates to '2023 Semi-Annual Report Summary'. It contains detailed financial data for the half-year period ending June 30, 2023, including assets, liabilities, net profit, earnings per share, and other financial metrics. It also includes company business descriptions, shareholder structure, and other operational details. The document explicitly states it is a summary of the half-year report and references the full report for more details. The length is over 5,000 characters and contains substantive financial data and analysis, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-28 Chinese
第二届董事会第二十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from Jiangxi Xinganjiang Pharmaceutical Co., Ltd. It details the convening and attendance of the board meeting, the approval of the 2023 semi-annual report and a special report on the use of raised funds, and voting results. It references the actual semi-annual report and special report being published separately on the Beijing Stock Exchange information disclosure platform. The document itself does not contain the financial statements or substantive financial data but is a formal announcement of board resolutions approving these reports. Therefore, it is not the interim/quarterly report itself but a board/management information announcement regarding board decisions and approvals. The document length is short (1420 characters), consistent with a meeting resolution announcement rather than a full report.
2023-08-28 Chinese
2023年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2023 半年度报告摘要' which translates to '2023 Semi-Annual Report Summary'. It contains detailed financial data for the half-year period ending June 30, 2023, including assets, liabilities, net profit, earnings per share, and other financial metrics. It also includes company business descriptions, shareholder structure, and other operational details. The document length is 5551 characters, which is sufficient to contain substantive financial data and analysis. The document explicitly states it is a half-year report summary derived from the full half-year report, indicating it is a form of interim or quarterly report. There is no indication that this is merely an announcement of a report or a certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-28 Chinese
2023年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "江西新赣江药业股份有限公司 2023 年半年度报告" which translates to "Jiangxi Xinganjiang Pharmaceutical Co., Ltd. 2023 Semi-Annual Report." It contains detailed financial data, including income statements, balance sheets, cash flow analysis, business overview, risk factors, and operational details for the period January 1, 2023 to June 30, 2023. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. It explicitly states it is a half-year report (semi-annual report), which corresponds to an Interim / Quarterly Report (IR) in the classification scheme. The document includes actual financial statements and substantive financial data and analysis, not just references or certifications. Therefore, the correct classification is Interim / Quarterly Report (IR). H1 2023
2023-08-28 Chinese
独立董事关于第二届董事会第二十四次会议相关事项的 独立意见
Regulatory Filings Classification · 95% confidence The document is an independent directors' opinion on a specific board meeting agenda item regarding the company's mid-year report on the storage and actual use of raised funds. It references a '2023 mid-year special report on raised funds usage' but does not contain the report itself, only an opinion on it. The document is short (507 characters) and serves as an announcement or opinion related to a specific agenda item rather than a full financial report. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement related to governance and fund usage but not a full report or financial statement.
2023-08-28 Chinese
第二届监事会第十六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Jiangxi Xinganjiang Pharmaceutical Co., Ltd. It details the meeting date, attendance, and the approval of two proposals: the 2023 semi-annual report and a special report on the use of raised funds. The document references the actual reports being published separately on the Beijing Stock Exchange information disclosure platform with specific announcement numbers. The document itself is short (1328 characters) and does not contain the full semi-annual report or detailed financial data, but rather announces the meeting resolutions and points to where the reports can be found. According to the 'Menu vs Meal' rule, this is an announcement of meeting resolutions and report approvals, not the report itself. It is not a full interim/quarterly report (IR) or annual report (10-K), nor is it a call transcript or other category. It is best classified as a Regulatory Filing (RNS) because it is a formal regulatory announcement of meeting resolutions and approvals without substantive financial data included.
2023-08-28 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.